Nonalcoholic fatty liver disease (NAFLD) is the leading chronic liver disease worldwide. Its
more advanced subtype, nonalcoholic steatohepatitis (NASH), connotes progressive liver …

Nonalcoholic fatty liver disease (NAFLD) and its progressive form nonalcoholic
steatohepatitis (NASH) comprise a spectrum of chronic liver diseases in the global …

Nanoplastics have raised considerable concerns since their ubiquity in the environment and
potential hazard to health. It has been proven that polystyrene nanoparticles (PS-NPs) can …

The treatment for hepatocellular carcinoma (HCC) is promising in recent years, but still
facing critical challenges. The first targeted therapy, sorafenib, prolonged the overall survival …

Alcohol-related liver disease (ALD) is a major cause of liver disease and represents a global
burden, as treatment options are scarce. Whereas 90% of ethanol abusers develop …

Simple Summary Hepatocellular carcinoma (HCC) is an aggressive human cancer and is
caused as consequences of chronic liver diseases. Although HCC is more common in …

Nonalcoholic fatty liver disease (NAFLD) includes a broad spectrum of liver dysfunctions
and it is predicted to become the primary cause of liver failure and hepatocellular carcinoma …

Mitochondria are subcellular organelles known for their central role in several energetic
processes. Accumulating evidence supports a key role for mitochondria in the physiological …

Metabolic dysfunction-associated fatty liver disease (MAFLD) is among the most widespread
metabolic disease globally, and its associated complications including insulin resistance …

The abnormal expansion of body fat paves the way for several metabolic abnormalities
including overweight, obesity, and diabetes, which ultimately cluster under the umbrella of …